E
Ernesta Fagiani
Researcher at University of Basel
Publications - 10
Citations - 931
Ernesta Fagiani is an academic researcher from University of Basel. The author has contributed to research in topics: Angiogenesis & Cancer cell. The author has an hindex of 8, co-authored 10 publications receiving 761 citations. Previous affiliations of Ernesta Fagiani include French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Angiopoietins in angiogenesis.
TL;DR: Its central role in the regulation of physiological and pathological angiogenesis makes the angiopoietin/Tie signaling pathway a therapeutically attractive target for the treatment of vascular disease and cancer.
Journal ArticleDOI
Targeting Metabolic Symbiosis to Overcome Resistance to Anti-angiogenic Therapy
Laura Pisarsky,Ruben Bill,Ernesta Fagiani,Sarah Dimeloe,Ryan Goosen,Jörg Hagmann,Christoph Hess,Gerhard Christofori +7 more
TL;DR: A potent anti-angiogenic efficacy of the multi-kinase inhibitors nintedanib and sunitinib in a mouse model of breast cancer is demonstrated and genetic ablation of MCT4 expression overcomes adaptive resistance against anti-Angiogenic therapy.
Journal ArticleDOI
Angiopoietin-1 and -2 Exert Antagonistic Functions in Tumor Angiogenesis, yet Both Induce Lymphangiogenesis
TL;DR: It is established that Ang-2 antagonizes Ang-1 function, leading to excessive vessel sprouting with impaired pericyte recruitment and vessel stabilization, defining an important pathophysiologic pathway required for efficient tumorigenesis.
Journal ArticleDOI
The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer
Stefanie Tiede,Nathalie Meyer-Schaller,Ravi Kiran Reddy Kalathur,Ravi Kiran Reddy Kalathur,Robert Ivanek,Robert Ivanek,Ernesta Fagiani,Philip Schmassmann,Patrick Stillhard,Simon Häfliger,Norbert Kraut,Norbert Schweifer,Irene Waizenegger,Ruben Bill,Gerhard Christofori +14 more
TL;DR: Assessment and characterized the therapeutic potential and the biological effects of BI 853520, a novel small chemical inhibitor of FAK, in several preclinical mouse models of breast cancer show a significant reduction in primary tumor growth caused by an anti-proliferative activity by BI853520.
Journal ArticleDOI
Proangiogenic Factor PlGF Programs CD11b+ Myelomonocytes in Breast Cancer during Differentiation of Their Hematopoietic Progenitors
Julien Laurent,Eveline Faes-van't Hull,Cédric Touvrey,François Kuonen,Qiang Lan,Girieca Lorusso,Marie Agnès Doucey,Laura Ciarloni,Natsuko Imaizumi,Gian Carlo Alghisi,Ernesta Fagiani,Khalil Zaman,Roger Stupp,Masabumi Shibuya,Jean François Delaloye,Gerhard Christofori,Curzio Rüegg,Curzio Rüegg,Curzio Rüegg +18 more
TL;DR: The results show that cancer cells can program proangiogenic activity in CD11b(+) myelomonocytes during differentiation of their progenitor cells in a PlGF-dependent manner and impact breast cancer biology, detection, and treatment.